CD36 knockdown by siRNA across multiple GBM xenograft specimens impacts on the CSC status by 1) reducing integrin α6 expression; 2) attenuating tumorspheres formation; 3) decreasing stem cell frequency; 4) abrogating tumor initiation capacity; and 5) decreasing key CSC maintenance signaling pathways like SOX2, phospho-AKT and phospho-STAT3 (Hale et al., 2014). Here, CD36 is linked to glioblastoma.